Kai Rejeski
Academic History
Kai Rejeski, MD, MHBA is the principal investigator of the Laboratory of Precision Immunotherapy in the Department of Hematology/Oncology at the LMU University Hospital in Munich, Germany, where he also works as a clinician-scientist. In addition, he holds an appointment as a Visiting Investigator in the Adult BMT and Cellular Therapy Service at Memorial Sloan Kettering Cancer Center in New York.
Speaking on CAR T-cell therapy-related toxicities
Dr Rejeski is known for his work elucidating hematologic toxicities of CAR T-cell therapy and led the international effort to define them as a distinct toxicity category termed immune effector cell-associated hematotoxicity, or ICAHT. Furthermore, he developed the CAR-HEMATOTOX model for the prediction of post-CAR-T cytopenias, which has subsequently also been validated for predicting infections, NRM, and response to CAR-T across multiple disease entities. His research group utilizes modern computational methods to examine the unique toxicity profile of T-cell based immunotherapies like CAR-T therapy and bispecific antibodies, and studies how they relate to clinical outcomes.
